Ipilimumab: will benefits outweigh risks in the eyes of the FDA?

Author：

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1307, 2010-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Aluminium in Over-the-Counter Drugs: Risks Outweigh Benefits?

By Reinke C.M.

Drug Safety, Vol. 26, Iss. 14, 2003-01 ,pp. : 1011-1025

Adis International

Access to resources Recommend Favorite

Risk of Melanoma with Psoralen/Ultraviolet A Therapy for Psoriasis: Do the Known Risks Now Outweigh the Benefits?

By Lindelöf B.

Drug Safety, Vol. 20, Iss. 4, 1999-04 ,pp. : 289-297

Adis International

Access to resources Recommend Favorite

Newer Biological Agents in the Treatment of Rheumatoid Arthritis: Do the Benefits Outweigh the Risks?

By Nurmohamed Michael T.

Drugs, Vol. 69, Iss. 15, 2009-10 ,pp. : 2035-2043

Adis International

Access to resources Recommend Favorite

Iodine Supplementation: Benefits Outweigh Risks

By Delange F.

Drug Safety, Vol. 22, Iss. 2, 2000-02 ,pp. : 89-95

Adis International

Access to resources Recommend Favorite

Monovalent rotavirus vaccine benefits outweigh risks

Reactions Weekly, Vol. 1, Iss. 1357, 2011-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite